Investigation of Asprosin a Novel Adipokine in Periodontitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

65 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2022-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Asprosin, a recently discovered glucogenic adipokine, is mainly synthesized by white adipose tissue and released during fasting. Appetite, glucose metabolism, insulin resistance, cell apoptosis, etc. asprosin is associated with diseases such as diabetes, obesity, polycystic ovary syndrome, and cardiovascular diseases. Periodontal tissue may act as a source of endocrine-like inflammatory mediators (such as TNF-α, IL-6 and IL-1) that are important in periodontal inflammation and can affect glucose and lipid metabolism. Production of TNF-α and IL-6 in adipose tissues strengthens the relationship between obesity, T2DM and periodontitis.we postulated that asprosin may be candidate for explaining the triangular relationship among obesity, T2DM, and periodontal disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Association of Asprosin in Periodontitis and Acute Coronary Syndrome

NCT05647902

Cardiovascular Diseases Periodontal Diseases

COMPLETED

EVALUATION of GINGIVAL CREVICULAR FLUID and SERUM ASPROSIN LEVELS in OBESE and NORMAL-WEIGHT INDIVIDUALS with PERIODONTITIS

NCT06879951

Periodontitis Obesity

COMPLETED

Asprosin, Adropin, Irisin Levels in Periodontitis

NCT06250764

Periodontal Diseases Gingivitis Obesity

COMPLETED

Changes in Salivary Asprosin, IL-39, IL-40 and IL-1β Levels in Diabetic Patients with Periodontitis

NCT06735313

Diabetes Mellitus Periodontal Disease Asprosin +1 more

NOT_YET_RECRUITING NA

Asprosin Level in Individuals with Periodontal Disease

NCT06627972

Periodontitis Periodontal Health Gingivitis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Periodontal disease is a chronic, multifactorial, and infectious disease caused by bacteria. It is characterized by the formation of an inflammatory response in the supporting bone and connective tissue against microbial dental plaque, and the nature of the resulting inflammatory response determines the course of periodontal disease. Type 2 Diabetes Mellitus (T2DM), obesity, and periodontal disease are closely related, presenting a triad association. Obesity is the crucial cause of T2DM and periodontitis is the sixth complication of diabetes. Asprosin circulates in the blood at nanomolar levels and is taken to the liver, where it activates the G protein-cAMP-PKA pathway, causing rapid glucose release into the circulation. Insulin-resistant humans and mice have been reported to have pathologically elevated plasma asprosin levels. It will be investigated whether asprosin, which we know to be effective on glucose metabolism, is affected by the periodontal condition.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontitis Obesity Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Periodontitis group

35 subjects had periodontitis. Periodontitis will be staged by including patients with a periodontal pocket (PD) measurement of 4 mm and above, accompanied by attachment loss and radiographic bone loss.

Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis

Intervention Type DIAGNOSTIC_TEST

Serum and saliva samples will be collected from both groups for biochemical analysis.

Healthy group

30 subjects had healthy periodontal tissue.Healthy controls included volunteers with clinically healthy gingiva on an intact periodontium who had BOP \< 10% and PD ≤ 3 mm, no sites with attachment loss, no radiographic sign of alveolar bone destruction, and no history of periodontitis.

Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis

Intervention Type DIAGNOSTIC_TEST

Serum and saliva samples will be collected from both groups for biochemical analysis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis

Serum and saliva samples will be collected from both groups for biochemical analysis.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All individuals were generally healthy,
* non-smoking

Exclusion Criteria

* Pregnant or breastfeeding women
* None had undergone periodontal therapy and/or antibiotic therapy in the past 6 months.
* None has a contagious disease such as HIV or AIDS

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No